Porayko MK - Search Results

1

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.

Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K; CONFIRM Study Investigators. Wong F, et al. Among authors: porayko mk. N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290. N Engl J Med. 2021. PMID: 33657294 Clinical Trial.

2

Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review.

Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, Wiesner RH. Krowka MJ, et al. Among authors: porayko mk. Mayo Clin Proc. 1997 Jan;72(1):44-53. doi: 10.4065/72.1.44. Mayo Clin Proc. 1997. PMID: 9005286 Review.

3

Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.

Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Dahlke LJ, Wilson SM, Steers JL, Krom RA. Graziadei IW, et al. Among authors: porayko mk. Transplantation. 1997 Sep 15;64(5):726-31. doi: 10.1097/00007890-199709150-00011. Transplantation. 1997. PMID: 9311710 Clinical Trial.

4

Management of ascites in patients with cirrhosis. What to do when diuretics fail.

Porayko MK, Wiesner RH. Porayko MK, et al. Postgrad Med. 1992 Dec;92(8):155-8, 161-6. doi: 10.1080/00325481.1992.11701557. Postgrad Med. 1992. PMID: 1454665 Review.

5

Intravascular volume regulation in cirrhotic patients with functional renal failure.

Porayko MK. Porayko MK. Transplant Proc. 1993 Apr;25(2):1727-9. Transplant Proc. 1993. PMID: 8470144 Review.

6

Beyond 1 year after liver transplantation.

Eid A, Steffen R, Porayko MK, Beers TR, Kaese DE, Wiesner RH, Krom RA. Eid A, et al. Among authors: porayko mk. Mayo Clin Proc. 1989 Apr;64(4):446-50. doi: 10.1016/s0025-6196(12)65735-8. Mayo Clin Proc. 1989. PMID: 2654501

7

Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.

Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH. Porayko MK, et al. Mayo Clin Proc. 1994 Feb;69(2):105-11. doi: 10.1016/s0025-6196(12)61034-9. Mayo Clin Proc. 1994. PMID: 7508536 Clinical Trial.

8

Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection.

Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Sandborn WJ, et al. Among authors: porayko mk. Hepatology. 1994 Apr;19(4):925-32. Hepatology. 1994. PMID: 8138267

9

Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation.

Wiesner RH, Marin E, Porayko MK, Steers JL, Krom RA, Paya CV. Wiesner RH, et al. Among authors: porayko mk. Gastroenterol Clin North Am. 1993 Jun;22(2):351-66. Gastroenterol Clin North Am. 1993. PMID: 8389735 Review.

10

Use of fatty donor liver is associated with diminished early patient and graft survival.

Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, Gores GJ, Krom RA. Marsman WA, et al. Among authors: porayko mk. Transplantation. 1996 Nov 15;62(9):1246-51. doi: 10.1097/00007890-199611150-00011. Transplantation. 1996. PMID: 8932265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page